For those of us using tE2 as a primary therapy to control advanced prostate cancer, there is new information in Clinical Oncology, Vol 36, Issue 1 „“ A repurposing Programme Evaluating Transdermal Oestradial Patches for the Treatment of Prostate Cancer within the PATCH and STAMPEDE Trials“. It‘s a long read but very informative on trial design, history and progress to date.
My initial reading is that the news is all good with confirmation of efficacy, improved SE profile regarding Bone Mass, reduced hot flashes, and absence of any increased cardiovascular problems vs SOC LHRH, and reported improved QOL. The study population (n) has been split into a comparison of those with metastases vs localized for better analysis of the advanced prostate cancer group. If I remember correctly the population includes those using tE2 in addition to advanced therapies ( aberraterone, xtandi, taxanes, etc.)
Interesting to note that some of the big Pharmaceuticals are involved in the funding in addition to College of London and UK.